Table 3.
Univariate and multivariate analyses for overall survival of the entire cohort
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (year) | 1.060 (1.030–1.090) | < 0.001 | 1.057 (0.946–1.024) | < 0.001 |
| Sex | 0.982 (0.726–1.330) | 0.905 | ||
| BMI (kg/m2) | 0.983 (0.942–1.030) | 0.446 | ||
| Diabetes | 1.170 (0.871–1.570) | 0.295 | ||
| Hypertension | 0.759 (0.573–1.010) | 0.056 | ||
| Cardiovascular attack | 1.330 (0.703–2.510) | 0.381 | ||
| Other malignancy | 1.400 (0.810–2.410) | 0.229 | ||
| Renal failure on dialysis | 1.920 (0.984–3.760) | 0.056 | ||
| Alcohol | 0.937 (0.711–1.240) | 0.645 | ||
| Smoking | 0.922 (0.700–1.220) | 0.565 | ||
| Etiology | 0.002 | |||
| Hepatitis B | 1 | – | ||
| Hepatitis C | 1.802 (1.295–2.507) | < 0.001 | ||
| Others | 1.314 (0.917–1.883) | 0.137 | ||
| Variceal bleeding | 1.760 (0.437–7.110) | 0.426 | ||
| Ascites | 1.910 (1.060–3.440) | 0.030 | ||
| MELD score | 1.100 (1.050–1.160) | < 0.001 | 1.078 (0.928–1.009) | 0.027 |
| Number of tumors | 1.250 (0.947–1.650) | 0.116 | ||
| Size of tumor (cm) | 1.060 (1.020–1.110) | 0.006 | 1.083 (0.923–1.026) | 0.004 |
| Albumin (g/dL) | 0.467 (0.358–0.611) | < 0.001 | 0.523 (1.912–0.383) | < 0.001 |
| Platelet (uL) | 0.996 (0.993–0.999) | 0.004 | 0.996 (1.004–0.993) | 0.006 |
| BCLC | 0.022 | 0.015 | ||
| stage 0 | 1 | – | 1 | – |
| stage A | 1.691 (1.012–2.824) | 0.045 | 1.711 (0.585–1.012) | 0.045 |
| stage B | 2.062 (1.221–3.480) | 0.007 | 2.003 (0.499–1.148) | 0.014 |
| Infiltrative type of HCC | 1.210 (0.300–4.870) | 0.791 | ||
| Serum AFP (ng/mL) | 1.000 (1.000–1.000) | 0.573 | ||
| MDVA | 1.501 (1.118–2.014) | 0.007 | 1.515 (0.660–1.112) | 0.009 |
| Objective tumor response | 0.614 (0.448–0.843) | 0.003 | 0.680 (1.471–0.488) | 0.023 |
AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; BMI, body mass index; HCC, hepatocellular carcinoma; MDVA, muscle depletion with visceral adiposity; MELD, model for end-stage liver disease